Trans-acting T-cell-specific transcription factor GATA-3 (GATA3)

Trans-acting T-cell-specific transcription factor GATA-3, commonly referred to as GATA3, is a master regulator of cell fate and differentiation within the immune system and several epithelial tissues [1, 6]. In the immune compartment, GATA3 is essential for the differentiation of T helper 2 (Th2) cells and the development of innate lymphoid cells, where it orchestrates the expression of Type 2 cytokines [2, 15]. Beyond its immunological roles, it is critical for the morphogenesis of the mammary gland, the inner ear, and the renal system [8, 11]. Pathologically, GATA3 is a central driver of airway inflammation in asthma and allergic diseases and is frequently dysregulated in various malignancies, acting as a tumor suppressor in luminal breast cancer but sometimes promoting progression in other contexts like head and neck squamous cell carcinoma [2, 13, 20]. Therapeutic interventions primarily target GATA3 mRNA translation using DNAzymes like SB010 (hgd40), or indirectly modulate its function through corticosteroids and HDAC inhibitors that affect its nuclear translocation and DNA-binding affinity [2, 21, 25]. Due to its multifaceted roles in development and homeostasis, therapeutic targeting requires precision to avoid developmental defects, such as those seen in HDR syndrome, or systemic immune dysregulation [11, 15].

Other names

GATA binding protein 3GATA-binding factor 3HDRHDRSGATA3

GATA3 function is modulated through several strategies: direct cleavage of GATA3 mRNA by DNAzymes (e.g., SB010) to prevent protein translation [2, 19]; suppression of nuclear translocation by corticosteroids which compete for importin-mediated transport [21]; impairment of DNA-binding ability via acetylation induced by HDAC inhibitors [25]; and epigenetic reactivation of expression using DNMT inhibitors in silenced tumor contexts [3, 5].